In people with an autosomal-dominant AD mutation, Aβ and tau start accumulating long before the estimated onset of symptoms.
The neurodegeneration marker appears to track disease severity in AD and MS patients with great sensitivity.
Rather than changing one by one, many biomarkers—including cognition, tau PET, hippocampal atrophy, and CSF p-tau—shift together, around the time of symptom onset in young adults with familial AD.
CRISPR-Cas9 gene editing rids embryos of a mutation causing heart disease, evoking a future where autosomal-dominant disease is prevented at the DNA level. What about AD, FTD, and ALS?
As data pours in, DIAN leaders strive to share and publish it without accidentally disclosing mutation status. The more is learned about preclinical AD, the harder this may get.
Armed with what they consider comprehensive data sets from the DIAN initiative, researchers are beginning a quest to settle an old question that may become key to drug approvals for late-onset AD.
At AAIC, updated imaging data in autosomal-dominant AD shows that longitudinal MRI in large numbers of people confirms atrophy patterns. Tau PET is more variable in DIAN participants than in the Colombian families.
Serial measurements on hundreds of people in the Dominantly Inherited Alzheimer’s Network put proposed staging diagrams on an empirical footing. CSF markers sTREM2 and VILIP-1 track tau.
At AAIC, 28 scientific presentations and five attendant meetings of the Dominantly Inherited Alzheimer’s Network showed how data is rolling in while the platform expands to more countries and a second therapeutic trial.
Tiny injuries to capillaries in white matter, and to cells in gray matter, have come to be the focus of new imaging measures being explored in early presymptomatic AD.
Regulatory and pharma scientists fielded pleas from families with autosomal-dominant Alzheimer’s disease just prior to the AAIC conference.
Bypass budget promises tide may be turning on an underfunded disease as families with autosomal-dominant Alzheimer’s discuss how to navigate their daily challenges.
A sense of shared purpose energized a day of exchange between families with autosomal-dominant AD and researchers engaged in the Dominantly Inherited Alzheimer Network.
In children as young as 9 who carry a presenilin 1 mutation, researchers detect subtle functional and structural brain changes.
Hollywood turns its attention to a rare form of dementia, giving a personal look at the impact of the disease.